Advertisement
UK markets close in 2 hours 31 minutes

  • FTSE 100

    8,077.15
    +36.77 (+0.46%)
     

  • FTSE 250

    19,683.29
    -36.08 (-0.18%)
     

  • AIM

    755.03
    +0.34 (+0.05%)
     

  • GBP/EUR

    1.1670
    +0.0025 (+0.22%)
     

  • GBP/USD

    1.2478
    +0.0016 (+0.13%)
     

  • Bitcoin GBP

    50,879.53
    -2,328.21 (-4.38%)
     

  • CMC Crypto 200

    1,356.76
    -25.82 (-1.87%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.82
    +0.01 (+0.01%)
     

  • GOLD FUTURES

    2,343.30
    +4.90 (+0.21%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,927.06
    -161.64 (-0.89%)
     

  • CAC 40

    7,992.99
    -98.87 (-1.22%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

U.S. FDA panel backs Valeant psoriasis drug with risk management

Reuters - UK Focus

July 19 (Reuters) - Valeant Pharmaceuticals International (NYSE: VRX - news) Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S (Other OTC: UBGXF - news) . Food and Drug Administration concluded on Tuesday.

The FDA is not obliged to follow the advice of its advisory committees but typically does so. (Reporting by Toni Clarke in Washington; Editing by Alan Crosby)